BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8938565)

  • 1. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer.
    Schuler M; Peschel C; Schneller F; Fichtner J; Färber L; Huber C; Aulitzky WE
    J Interferon Cytokine Res; 1996 Nov; 16(11):903-10. PubMed ID: 8938565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II.
    Kreuzer KA; Dayer JM; Rockstroh JK; Sauerbruch T; Spengler U
    Clin Exp Immunol; 1997 Jul; 109(1):54-8. PubMed ID: 9218824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble cytokine receptors and the low 3,5,3'-triiodothyronine syndrome in patients with nonthyroidal disease.
    Boelen A; Platvoet-Ter Schiphorst MC; Wiersinga WM
    J Clin Endocrinol Metab; 1995 Mar; 80(3):971-6. PubMed ID: 7883859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11.
    Schwertschlag US; Trepicchio WL; Dykstra KH; Keith JC; Turner KJ; Dorner AJ
    Leukemia; 1999 Sep; 13(9):1307-15. PubMed ID: 10482979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
    Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
    Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
    Keever-Taylor CA; Witt PL; Truitt RL; Ramanujam S; Borden EC; Ritch PS
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):231-43. PubMed ID: 8811498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
    Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
    Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of erythropoietin on immunological system of patients with chronic renal failure].
    Debska-Slizień A; Rutkowski B; Manitius J; Zdrojewski Z; Szołkiewicz M; Bułło B; Lizakowski S; Myśliwska J; Myśliwski A; Bryl E; Trzonkowski P; Bakowska A; Rachoń D
    Pol Merkur Lekarski; 2003 Oct; 15(88):326-7; discussion 327-9. PubMed ID: 14974359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential early posttransplant cytokine responses in living and cadaver donor renal allografts.
    Sadeghi M; Daniel V; Weimer R; Wiesel M; Hergesell O; Opelz G
    Transplantation; 2003 Apr; 75(8):1351-5. PubMed ID: 12717229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects.
    Banks RE; Forbes MA; Patel PM; Storr M; Hallam S; Clarke D; Novick D; Ingham E; Bowmer C; Southgate J; Trejdosiewicz LK; Illingworth J; Perren TJ; Selby PJ
    Cytokine; 2000 Apr; 12(4):388-96. PubMed ID: 10805221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
    Weber J; Yang JC; Topalian SL; Parkinson DR; Schwartzentruber DS; Ettinghausen SE; Gunn H; Mixon A; Kim H; Cole D
    J Clin Oncol; 1993 Mar; 11(3):499-506. PubMed ID: 7680375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
    Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
    Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
    Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
    Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modulatory impact of recombinant human interleukin-6 on the immune system of cancer patients.
    Nieken J; Mulder NH; Pietens J; Limburg PC; de Leij L; de Vries EG
    J Immunother; 1999 Jul; 22(4):363-70. PubMed ID: 10404438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Soluble cytokinin receptors in renal vasculitis and lupus nephritis].
    Tesar V; Jirsa M; Masek Z; Bartůnková J; Stejskalová A; Dostál C; Zabka J; Chábová V; Rysavá R
    Cas Lek Cesk; 1998 May; 137(9):271-5. PubMed ID: 9650355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission.
    Tsai SY; Chung KH; Huang SH; Chen PH; Lee HC; Kuo CJ
    Bipolar Disord; 2014 Dec; 16(8):800-8. PubMed ID: 25130211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
    Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
    Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.